Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
2.
RMD Open ; 7(1)2021 01.
Article in English | MEDLINE | ID: covidwho-1011014

ABSTRACT

AIMS: In Danish patients with inflammatory rheumatic diseases to explore self-protection strategies and health behaviour including adherence to disease-modifying antirheumatic treatment (DMARD) during the initial phase of the COVID-19 pandemic and again after the reopening of the society started. Furthermore, to identify characteristics of patients with high levels of anxiety and self-isolation. METHODS: Patients in routine care followed prospectively in the nationwide DANBIO registry were invited to answer an online questionnaire regarding disease activity and COVID-19 infection, behaviour in March and June 2020. Responses were linked to patient data in DANBIO. Characteristics potentially associated with anxiety, self-isolation and medication adherence (gender/age/diagnosis/education/work status/comorbidity/DMARD/smoking/EQ-5D/disease activity) were explored with multivariable logistic regression analyses. RESULTS: We included 12 789 patients (8168 rheumatoid arthritis/2068 psoriatic arthritis/1758 axial spondyloarthritis/795 other) of whom 65% were women and 36% treated with biological DMARD. Self-reported COVID-19 prevalence was 0.3%. Patients reported that they were worried to get COVID-19 infection (March/June: 70%/45%) and self-isolated more than others of the same age (48%/38%). The fraction of patients who changed medication due to fear of COVID-19 were 4.1%/0.6%. Female gender, comorbidities, not working, lower education, biological treatment and poor European Quality of life, 5 dimensions were associated with both anxiety and self-isolation. CONCLUSION: In >12 000 patients with inflammatory arthritis, we found widespread anxiety and self-isolation, but high medication adherence, in the initial phase of the COVID-19 pandemic. This persisted during the gradual opening of society during the following months. Attention to patients' anxiety and self-isolation is important during this and potential future epidemics.


Subject(s)
COVID-19/epidemiology , Health Behavior , Pandemics , Rheumatic Diseases/psychology , SARS-CoV-2 , Adult , Aged , Aged, 80 and over , Antirheumatic Agents/therapeutic use , Anxiety/epidemiology , Arthritis, Psoriatic/drug therapy , Arthritis, Psoriatic/epidemiology , Arthritis, Psoriatic/psychology , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/epidemiology , Arthritis, Rheumatoid/psychology , COVID-19/prevention & control , COVID-19/psychology , Denmark/epidemiology , Female , Health Surveys/statistics & numerical data , Humans , Male , Medication Adherence/statistics & numerical data , Middle Aged , Quarantine/statistics & numerical data , Registries/statistics & numerical data , Rheumatic Diseases/drug therapy , Rheumatic Diseases/epidemiology , Spondylarthropathies/drug therapy , Spondylarthropathies/epidemiology , Spondylarthropathies/psychology
3.
Ann Rheum Dis ; 79(11): 1393-1399, 2020 11.
Article in English | MEDLINE | ID: covidwho-705256

ABSTRACT

OBJECTIVES: To describe patients with autoimmune inflammatory rheumatic diseases (AIRD) who had COVID-19 disease; to compare patients who required hospital admission with those who did not and assess risk factors for hospital admission related to COVID-19. METHODS: An observational longitudinal study was conducted during the pandemic peak of severe acute respiratory syndrome coronavirus 2 (1 March 2020 to 24 April). All patients attended at the rheumatology outpatient clinic of a tertiary hospital in Madrid, Spain with a medical diagnosis of AIRD and with symptomatic COVID-19 were included. The main outcome was hospital admission related to COVID-19. The covariates were sociodemographic, clinical and treatments. We ran a multivariable logistic regression model to assess risk factors for the hospital admission. RESULTS: The study population included 123 patients with AIRD and COVID-19. Of these, 54 patients required hospital admission related to COVID-19. The mean age on admission was 69.7 (15.7) years, and the median time from onset of symptoms to hospital admission was 5 (3-10) days. The median length of stay was 9 (6-14) days. A total of 12 patients died (22%) during admission. Compared with outpatients, the factors independently associated with hospital admission were older age (OR: 1.08; p=0.00) and autoimmune systemic condition (vs chronic inflammatory arthritis) (OR: 3.55; p=0.01). No statistically significant findings for exposure to disease-modifying antirheumatic drugs were found in the final model. CONCLUSION: Our results suggest that age and having a systemic autoimmune condition increased the risk of hospital admission, whereas disease-modifying antirheumatic drugs were not associated with hospital admission.


Subject(s)
Autoimmune Diseases/epidemiology , Coronavirus Infections/therapy , Hospitalization/statistics & numerical data , Pneumonia, Viral/therapy , Rheumatic Diseases/epidemiology , Age Factors , Aged , Aged, 80 and over , Ambulatory Care , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/epidemiology , Autoimmune Diseases/drug therapy , Betacoronavirus , COVID-19 , Diabetes Mellitus/epidemiology , Female , Glucocorticoids/therapeutic use , Heart Diseases/epidemiology , Humans , Hypertension/epidemiology , Length of Stay/statistics & numerical data , Longitudinal Studies , Lung Diseases/epidemiology , Lupus Erythematosus, Systemic/drug therapy , Lupus Erythematosus, Systemic/epidemiology , Male , Middle Aged , Mixed Connective Tissue Disease/drug therapy , Mixed Connective Tissue Disease/epidemiology , Multivariate Analysis , Pandemics , Polymyalgia Rheumatica/drug therapy , Polymyalgia Rheumatica/epidemiology , Protective Factors , Rheumatic Diseases/drug therapy , Risk Factors , SARS-CoV-2 , Sex Factors , Sjogren's Syndrome/drug therapy , Sjogren's Syndrome/epidemiology , Spain/epidemiology , Spondylarthropathies/drug therapy , Spondylarthropathies/epidemiology , Tumor Necrosis Factor Inhibitors/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL